LeMaitre Vascular Files 8-K for Reg FD Disclosure
Ticker: LMAT · Form: 8-K · Filed: Dec 16, 2024 · CIK: 1158895
| Field | Detail |
|---|---|
| Company | Lemaitre Vascular Inc (LMAT) |
| Form Type | 8-K |
| Filed Date | Dec 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $150 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, regulation-fd, exhibits
Related Tickers: LMAV
TL;DR
LMAV filed an 8-K for Reg FD disclosure and exhibits. No new material info in this snippet.
AI Summary
On December 16, 2024, LeMaitre Vascular, Inc. filed an 8-K report. The filing primarily serves as a notification of a Regulation FD Disclosure and the filing of Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates that LeMaitre Vascular is making a public disclosure under Regulation FD, which ensures fair disclosure of material information to all investors.
Risk Assessment
Risk Level: low — The filing is a routine procedural update and does not contain information about significant risks or negative developments.
Key Players & Entities
- LeMaitre Vascular, Inc. (company) — Registrant
- December 16, 2024 (date) — Date of earliest event reported
- Burlington, MA (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is December 16, 2024.
What is the principal executive office address for LeMaitre Vascular, Inc.?
The principal executive office address is 63 Second Avenue, Burlington, MA 01803.
What is the Commission File Number for LeMaitre Vascular, Inc.?
The Commission File Number for LeMaitre Vascular, Inc. is 001-33092.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 497 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-12-16 07:20:28
Key Financial Figures
- $150 million — lease announcing its intention to offer $150 million aggregate principal amount of Convertib
Filing Documents
- tm2430433d2_8k.htm (8-K) — 26KB
- tm2430433d2_ex99-1.htm (EX-99.1) — 9KB
- tm2430433d2_ex99-1img001.jpg (GRAPHIC) — 12KB
- 0001104659-24-128674.txt ( ) — 223KB
- lmat-20241216.xsd (EX-101.SCH) — 3KB
- lmat-20241216_lab.xml (EX-101.LAB) — 33KB
- lmat-20241216_pre.xml (EX-101.PRE) — 22KB
- tm2430433d2_8k_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure. On December 16, 2024, LeMaitre Vascular, Inc. (the "Company") issued a press release announcing its intention to offer $150 million aggregate principal amount of Convertible Senior Notes due 2030 (the "Notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. A copy of the press release is furnished as Exhibit 99.1 and incorporated herein by reference. Neither this Current Report on Form 8-K nor the press release constitutes an offer to sell, or the solicitation of an offer to buy, the Notes or the shares of the Company's common stock, if any, issuable upon conversion of the Notes.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release of LeMaitre Vascular, Inc. dated December 16, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LeMaitre Vascular, Inc. Date: December 16, 2024 By: /s/ Joseph P. Pellegrino, Jr. Name: Joseph P. Pellegrino, Jr. Title: Chief Financial Officer